Caricamento...
Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
BACKGROUND: To compare the overall survival (OS) of patients with advanced lung adenocarcinoma in China before and after the approved use of gefitinib, and analyze clinical factors that may affect OS. METHODS: Clinical data of 558 patients with advanced lung adenocarcinoma who received chemotherapy...
Salvato in:
| Pubblicato in: | Thorac Cancer |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4567010/ https://ncbi.nlm.nih.gov/pubmed/26445613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12267 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|